Wells Fargo analyst Larry Biegelsen upgrades Integra Lifesciences (NASDAQ:IART) from Equal-Weight to Overweight and raises the price target from $40 to $49.
Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.